Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapies
Description
The discussion centers on non-biologic therapies for Hidradenitis Suppurativa (HS), focusing on topical, local, and systemic treatments. It emphasizes the need for effective management strategies, particularly for patients with mild to moderate HS, and mentions various therapies available. Topical agents like Clindamycin and topical Resorzine are noted for their effectiveness in symptomatic relief, while newer options such as topical Ruxolitinib show promise based on preliminary studies. Local therapies, including Botulinum toxin and intralesional triamcinolone, also demonstrate benefits, especially for acute painful lesions. Systemic therapies encompass antibiotics, hormonal treatments, and systemic retinoids, which can be used as adjuncts to biologic treatments. Notable findings include the importance of rifampin in antibiotic regimens and the potential of Erdopenem for long-term management in refractory cases. Hormonal therapies are suggested for women with hormonal influences on HS, and systemic retinoids may benefit patients with a comedonal component. The talk highlights an increasing awareness of HS and the necessity for layered treatment approaches to improve patient outcomes, along with providing educational resources for clinicians and patients.
View moreConclusions
- Topical therapies for mild Hidradenitis Suppurativa (HS), such as Clindamycin and Resorcinol, can provide symptom relief.
- Clindamycin has shown effectiveness in reducing pain and pustules without affecting inflammatory nodules in Hurley Stage 1 and 2 disease.
- Topical Ruxolitinib may offer a promising option for patients with mild HS, achieving significant reductions in abscess and nodule counts.
- Intralesional Triamcinolone is effective for acute HS lesions, with higher doses needed to maximize pain relief and lesion size reduction.
- Combination therapy using systemic antibiotics like Clindamycin and Rifampin with biologic therapy (e.g., Adalimumab) enhances treatment outcomes in patients with moderate to severe HS.
- Ertapenem is effective as a rescue therapy for severe HS and serves as a bridge to more definitive care.
- Hormonal therapies, such as Spironolactone, can help manage HS symptoms in patients experiencing hormone-related flares.
- Systemic retinoids like Acitretin can be beneficial in HS but require careful monitoring due to side effects.
- Jemec, G.B.E., & Wendelbow, H. (1998). "Antimicrobial therapy in the management of hidradenitis suppurativa." JAAD, 1998.
- Clemmensen, O. (1983). "Treatment of hidradenitis suppurativa with clindamycin and rifampicin." IJD, 1983.
- Pascual, J., et al. (2017). "Resorcinol 15% topical treatment shows benefit in hidradenitis suppurativa patients." JAAD, 2017.
- Kirby, B., et al. (2024). "Topical ruxolitinib for hidradenitis suppurativa: a clinical trial presentation at EHSF 2024."
- Danesh, M., & Kimball, A.B. (2015). "Topical washes in the treatment of hidradenitis suppurativa." JAAD, 2015.
- Riis, P.T., et al. (2016). "Intralesional triamcinolone as an effective treatment for hidradenitis suppurativa." JAAD, 2016.
- Fajgenbaum, K., et al. (2019). "Intralesional corticosteroid therapy in hidradenitis suppurativa." Derm Surg, 2019.
- Ring, H.C., et al. (2015). "The microbiology of hidradenitis suppurativa: review of current literature." Exp Dermatology, 2015.
- Gener, G., et al. (2009). "Systemic antibiotics in the treatment of hidradenitis suppurativa." Dermatology, 2009.
- Caro, I., et al. (2019). "Is rifampin essential for clindamycin treatment in hidradenitis suppurativa?" JAAD, 2019.